[go: up one dir, main page]

RU2218919C2 - Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний - Google Patents

Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний Download PDF

Info

Publication number
RU2218919C2
RU2218919C2 RU2000106044/14A RU2000106044A RU2218919C2 RU 2218919 C2 RU2218919 C2 RU 2218919C2 RU 2000106044/14 A RU2000106044/14 A RU 2000106044/14A RU 2000106044 A RU2000106044 A RU 2000106044A RU 2218919 C2 RU2218919 C2 RU 2218919C2
Authority
RU
Russia
Prior art keywords
group
nitrogen atom
alkyl
ness
compound
Prior art date
Application number
RU2000106044/14A
Other languages
English (en)
Other versions
RU2000106044A (ru
Inventor
Гео Адам
Забине Кольчевски
Венсан МЮТЕЛЬ
Хайнц Штадлер
Йюрген Вихманн
Томас Иоганнес ВОЛЬТЕРИНГ
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2000106044A publication Critical patent/RU2000106044A/ru
Application granted granted Critical
Publication of RU2218919C2 publication Critical patent/RU2218919C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Изобретение относится к области медицины, а именно к фармакологии, и может иметь отношение к лечению неврологических заболеваний. Используют соединение общей формулы (I)
Figure 00000001

в которой R обозначает галоген или (низш.)алкил, n = 0-3; R1 обозначает (низш. )алкил, циклоалкил, бензил, необязательно замещенный гидроксигруппой, галогеном, (низш.)алкоксигруппой или (низш.)алкилом, бензоил, необязательно замещенный амино-, (низш.)алкиламино- или ди(низш.)алкиламиногруппой, ацетил или циклоалкилкарбонил и

Description

Текст описания в факсимильном виде (см. графическую часть) Т

Claims (6)

1. Лекарственное средство, обладающее антагонистической и/или агонистической активностью в отношении метаботропного глутаматного рецептора, содержащее в качестве терапевтически активного вещества соединение общей формулы
Figure 00000025
в которой R обозначает галоген или (низш.)алкил;
n=0-3;
R1 обозначает (низш.)алкил, циклоалкил, бензил, необязательно замещенный гидроксигруппой, галогеном, (низш.)алкоксигруппой или (низш.)алкилом, бензоил, необязательно замещенный амино-, (низш.)алкиламино- или ди(низш.)алкиламиногруппой, ацетил или циклоалкилкарбонил;
Figure 00000026
обозначает ароматический 5-членный фрагмент, который присоединен через атом азота и который, кроме связывающего атома азота, дополнительно содержит 1-3 атома азота,
а также его фармацевтически приемлемые соли.
2. Лекарственное средство по п.1, содержащее в качестве терапевтически активного вещества соединение общей формулы I, где R обозначает хлор, n=1 или 2,
R1 обозначает (низш.)алкил, циклогексил или бензил и
Figure 00000027
обозначает ароматическое 5-членное кольцо, которое присоединено через атом азота и которое, кроме связывающего атома азота, дополнительно содержит 2 или 3 атома азота.
3. Лекарственное средство по п.2, содержащее в качестве терапевтически активного вещества соединение, выбранное из группы, включающей
1-[2-(2,4-дихлорфенил)-2-циклогексилоксивинил]-1Н-[1,2,4]триазол,
1-[2-(2,4-дихлорфенил)-2-бензилоксивинил]-1Н-тетразол,
1-[2-(4-хлорфенил)-2-бутоксивинил]-1Н-тетразол,
1-[2-(4-хлорфенил)-2-бутоксивинил]-1Н-[1,2,4]триазол и
1-[2-(2,6-дихлорфенил)-2-бутоксивинил]-1Н-[1,2,4]триазол.
4. Соединения общей формулы I, в которых R и R1 имеют значения указанные в п.1,
Figure 00000028
обозначает ароматическое 5-членное кольцо, которое присоединено через атом азота и которое, кроме связывающего атома азота, дополнительно содержит 3 атома азота.
5. Соединения общей формулы I, в которых R и
Figure 00000029
имеют значения, указанные в п.1, а R1 обозначает циклоалкил.
6. Соединение по п.5, представляющее собой 1-[2-(2,4-дихлорфенил)-2-циклогексилоксивинил]-1Н-[1,2,4]триазол.
RU2000106044/14A 1997-08-14 1998-08-06 Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний RU2218919C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97114065.2 1997-08-14
EP97114065 1997-08-14

Publications (2)

Publication Number Publication Date
RU2000106044A RU2000106044A (ru) 2002-05-10
RU2218919C2 true RU2218919C2 (ru) 2003-12-20

Family

ID=8227219

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000106044/14A RU2218919C2 (ru) 1997-08-14 1998-08-06 Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний

Country Status (24)

Country Link
US (2) US6054588A (ru)
EP (1) EP1003505B1 (ru)
JP (1) JP3593031B2 (ru)
KR (1) KR100357650B1 (ru)
CN (1) CN1154489C (ru)
AR (1) AR016604A1 (ru)
AT (1) ATE262331T1 (ru)
AU (1) AU741532B2 (ru)
BR (1) BR9811933A (ru)
CA (1) CA2297732C (ru)
DE (1) DE69822638T2 (ru)
ES (1) ES2216305T3 (ru)
HR (1) HRP20000079A2 (ru)
HU (1) HUP0004412A3 (ru)
ID (1) ID28529A (ru)
IL (1) IL134168A0 (ru)
NO (1) NO20000738L (ru)
NZ (1) NZ502463A (ru)
PL (1) PL192029B1 (ru)
RU (1) RU2218919C2 (ru)
TR (1) TR200000405T2 (ru)
WO (1) WO1999008678A1 (ru)
YU (1) YU6100A (ru)
ZA (1) ZA987145B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS43903A (sr) * 2000-12-04 2006-12-15 F.Hoffmann-La Roche Ag. Feniletenil-ili feniletinil-derivati kao antagonisti glutamatnih receptora
AU2002327180A1 (en) * 2001-06-04 2003-01-21 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
DE10205057A1 (de) * 2002-02-07 2003-08-14 Bayer Cropscience Ag Substituierte 4-Hetaryl-pyrazoline
WO2004078715A1 (ja) 2003-03-07 2004-09-16 Astellas Pharma Inc. ２，６－ジ置換スチリルを有する含窒素へテロ環誘導体
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
HRP20080363T3 (hr) 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
ITVA20050050A1 (it) * 2005-08-05 2007-02-06 Lamberti Spa Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita'
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2008066750A1 (en) 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
HRP20160950T1 (hr) 2006-12-21 2016-10-07 F. Hoffmann-La Roche Ag Polimorfi antagonista mglur5 receptora
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8722894B2 (en) * 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
RU2492170C9 (ru) * 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102506473B (zh) * 2011-10-18 2014-06-11 江苏七彩科技有限公司 直接蒸发式冰蓄冷制冷系统及其制冷方法
CN102690240B (zh) * 2012-06-07 2014-09-10 郑州大学 三氮唑烯醚类、肟醚类化合物及其制备方法与应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
CN106279038A (zh) * 2016-08-16 2017-01-04 湖南中威制药有限公司 一种硝酸奥昔康唑原料药的合成方法
IL267195B2 (en) * 2016-12-14 2024-05-01 Sk Biopharmaceuticals Co Ltd Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US11147798B2 (en) 2016-12-14 2021-10-19 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
CN114901647B (zh) * 2019-10-24 2024-04-02 爱思开生物制药株式会社 具有改进的选择性的制备芳基2-四唑-2-基酮的方法
KR20230066244A (ko) 2021-11-06 2023-05-15 김경민 점선식 포장지

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330545A (en) * 1977-02-21 1982-05-18 Siegfried Aktiengesellschaft Heterocyclic imidazolyl vinyl ethers and use of same as fungicides or bactericides
DE2839388A1 (de) * 1978-09-11 1980-03-27 Siegfried Ag Imidazolylvinylaether und deren verwendung
CH648552A5 (de) * 1981-01-23 1985-03-29 Siegfried Ag Verfahren zur herstellung von imidazolylvinylethern.
EP0079856A1 (de) * 1981-11-12 1983-05-25 Ciba-Geigy Ag Mikrobizide Triazolyl-vinyläther
DE3417468A1 (de) * 1984-05-11 1985-11-14 Bayer Ag, 5090 Leverkusen Azolylvinylether
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists

Also Published As

Publication number Publication date
JP2001515037A (ja) 2001-09-18
CA2297732C (en) 2008-04-29
AU9159398A (en) 1999-03-08
DE69822638D1 (de) 2004-04-29
HUP0004412A2 (hu) 2001-07-30
CA2297732A1 (en) 1999-02-25
ZA987145B (en) 1999-02-15
EP1003505A1 (en) 2000-05-31
US6248901B1 (en) 2001-06-19
KR100357650B1 (ko) 2002-10-25
BR9811933A (pt) 2000-09-05
KR20010022877A (ko) 2001-03-26
NZ502463A (en) 2002-05-31
YU6100A (sh) 2002-10-18
CN1154489C (zh) 2004-06-23
NO20000738L (no) 2000-04-11
ES2216305T3 (es) 2004-10-16
TR200000405T2 (tr) 2000-08-21
CN1266368A (zh) 2000-09-13
PL192029B1 (pl) 2006-08-31
JP3593031B2 (ja) 2004-11-24
HRP20000079A2 (en) 2000-12-31
US6054588A (en) 2000-04-25
NO20000738D0 (no) 2000-02-14
DE69822638T2 (de) 2005-02-24
AU741532B2 (en) 2001-12-06
ID28529A (id) 2001-05-31
IL134168A0 (en) 2001-04-30
PL338637A1 (en) 2000-11-06
HUP0004412A3 (en) 2003-06-30
WO1999008678A1 (en) 1999-02-25
EP1003505B1 (en) 2004-03-24
ATE262331T1 (de) 2004-04-15
AR016604A1 (es) 2001-07-25

Similar Documents

Publication Publication Date Title
RU2218919C2 (ru) Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний
RU2000106044A (ru) Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний
RU2214400C2 (ru) Производные 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
US11957657B2 (en) Combination therapies using immuno-dash inhibitors and PGE2 antagonists
RU2325382C2 (ru) Производные 1h-1,2,4-триазол-3-карбоксамида в качестве лигандов рецептора каннабиноидов
ES2285522T3 (es) 1-(2,3-dimetil,fenil)-etil-1,3-dihidro-imidazol-2-tiona como agonista alfa 2a no sedante.
DE60012751T2 (de) Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz
RU2003107921A (ru) Селективные циклопептиды
EP2036902A3 (en) Urea compounds active as vanilloid receptor antagonist for the treatment of pain
KR960701009A (ko) 면역억제 작용을 갖는 신규한 2, 2'-비-1H- 피롤 유도체(Novel 2,2'-bi-1H-pyrrole derivatives with immunosuppressant activity)
JPH06293740A (ja) アゾール化合物、その製造方法及びその用途
BR9408343A (pt) Derivados 5-(2-imidazolinil amino) benzimidazol sua preparação e seu uso como agonistas alfa-2 adrenoceptor
RU2002110107A (ru) Производные бензодиазепина
JP2005536475A5 (ru)
JP2005518337A5 (ru)
JP2005524628A5 (ru)
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
RU2005102110A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
RU2221788C2 (ru) Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения
WO2003084527A1 (en) Severe sepsis preventive therapeutic agent
US4208417A (en) Indole derivatives and their use as anxiolytics
Hanna et al. Synthesis and pharmacological evaluation of some novel 5-(pyrazol-3-yl) thiadiazole and oxadiazole derivatives as potential hypoglycemic agents
CA2402099A1 (en) Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
CA2005976A1 (en) Agents containing imidazoline derivatives for systemic combating of ecto-parasites in host animals and novel imidazoline derivatives

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080807